StockData
Kura Oncology, Inc. logo

Kura Oncology, Inc. (KURA) stock

KURANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 1/30
$7.34−0.15 (-2.00%)

Close on Nov 18, 2026Market cap $652.97MP/E –Yield –

Kura Oncology enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Kura Oncology's enterprise value was $178.38M on Nov 11, 2026, against $516.38M a year earlier. Over the last 5 years it ranged from -$204.69M to $1.17B, with a median of $402.38M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$178.38M-51.0%
2025Dec 31, 2025$364.10M+57.4%
2024Dec 31, 2024$231.37M-62.9%
2023Dec 29, 2023$624.43M+55.2%
2022Dec 30, 2022$402.38M+3.8%
2021Dec 31, 2021$387.61M-74.7%
2020Dec 31, 2020$1.53B+302.8%
2019Dec 31, 2019$380.21M-26.8%
2018Dec 31, 2018$519.41M+21.0%
2017Dec 29, 2017$429.35M+280.3%
2016Dec 30, 2016$112.89M+40.0%
2015Dec 31, 2015$80.65M–

More Kura Oncology figures

See a number that looks wrong?